Prevalence and Clinical Impact of Cytomegalovirus Infection and Disease in Renal Transplantation: Ten Years of Experience in a Single Center

Cytomegalovirus disease in patients with glomerular diseases treated by immunosuppressive treatment

“…CMV prophylaxis decreases this rate to 4-7 % [13][14][15]. The incidence of CMV disease in the present study was 19.2 %.…”

“…Many transplantation centers, especially in the early post-transplant period (first 6 months), use prophylaxis against CMV. Solid organ transplant patients use valganciclovir prophylactic regimens, which are effective for prevention of CMV disease, even in patients with CMV-seropositive donors and CMV-seronegative recipients [14][15][16][17]. Baseline creatinine level was higher in the RPGN group, and these patients more frequently received steroid with CP.…”

Como promover a desospitalização devido ao transplante de órgãos sólidos? Panorama atual no Brasil e profilaxia da infecção pelo citomegalovírus com valganciclovir

“…Entre os fatores que influenciam no tempo de permanência hospitalar nos pacientes submetidos a transplante de órgãos sólidos (TOS) encontra-se a necessidade de profilaxia contra o citomegalovírus (CMV), um vírus ubíquo da família herpes vírus (HHV5) que pode ser transmitido pela transfusão de sangue, saliva, urina, transferência placentária, aleitamento materno e contato sexual, como também por transplante de células-tronco hematopoiéticas ou de órgãos sólidos (Alexopoulos et al, 2012;Giakoustidis et al, 2012). Sem a profilaxia adequada, aproximadamente 80% dos receptores de TOS podem desenvolver infecção pelo CMV (Junqueira et al, 2008;Roman et al, 2014).…”

Which CMV Viral Load Threshold Should Be Defined as CMV Infection in Kidney Transplant Patients?

“…Accepting a CMV viral load threshold of more than 10,000 copies/mL as CMV infection has the most sensitivity and specificity for predicting both white blood cell and platelet counts in kidney transplant patients. No CMV viral load threshold as the gold standard for CMV infection diagnosis has the discriminatory power for differing clinical and para-clinical parameters other than platelet and white blood cell count between presumably infected kidney transplant patients and those not infected.C YTOMEGALOVIRUS INFECTION (CMV) is prevalent in kidney transplant patients and is associated with mortality [1,2]. Several studies have shown that a standardized real-time polymerase chain reaction (PCR) assay is more appropriate than the antigen assay for detecting CMV.…”

“…C YTOMEGALOVIRUS INFECTION (CMV) is prevalent in kidney transplant patients and is associated with mortality [1,2]. Several studies have shown that a standardized real-time polymerase chain reaction (PCR) assay is more appropriate than the antigen assay for detecting CMV.…”